Association Between Asthma Exacerbations and Lung Function With Reslizumab Treatment In Patients With Uncontrolled Eosinophilic Asthma: Pooled Analysis of Two Phase 3 Trials

Reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, significantly reduced the risk of clinical asthma exacerbation (CAE) in patients with inadequately controlled eosinophilic asthma and ≥1 CAE in the prior 12 months, with greater treatment effect in patients with more historical CAEs. The objective of this analysis was to assess the association between baseline CAE rate and lung function (FEV1 change from baseline).